Kane Biotech Inc. KNBIF OTC

Kane Biotech Inc. (KNBIF) generated $-698.22K in operating cash flow for quarter ending 2025-09-30. After capital expenditures of $5.61K, free cash flow was $-703.83K.

Free cash flow margin was -8281.3% of revenue. Cash conversion ratio was 1.15x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (43/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (100/100) — Cash conversion ratio was 1.15x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.